The global ischemia reperfusion injury (IRI) treatment market, valued at USD 823.74 million in 2022, is anticipated to grow significantly, reaching approximately USD 1.58 billion by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 6.1% during the forecast period from 2023 to 2033.
The expansion of the ischemia reperfusion injury treatment market can be attributed to the increasing prevalence of conditions that can lead to IRI, including heart attacks, strokes, and organ transplants. As the global incidence of these conditions rises, so does the demand for effective treatment options to mitigate the damaging effects of IRI.
Additionally, advancements in technology and medical research are paving the way for the development of innovative therapies aimed at treating IRI. These breakthroughs are expected to further drive market growth in the coming years, providing healthcare professionals with new tools to improve patient outcomes.
In the historical period from 2018 to 2022, the market for ischemia reperfusion injury treatment registered a CAGR of 3.4%, reflecting a growing recognition of the need for effective management strategies. As research continues to evolve and more treatment options become available, the market is poised for significant growth, offering substantial opportunities for healthcare providers and pharmaceutical companies focused on enhancing care for patients affected by ischemia reperfusion injury.
Ischemia-reperfusion injury (IRI) occurs when blood supply to an organ or tissue is temporarily cut off, followed by the restoration of blood flow. This can lead to tissue damage and cell death. Ischemia-reperfusion injury treatment refers to therapies or interventions aimed at preventing or minimizing the damage caused by IRI.
The ischemia reperfusion injury treatment market includes a variety of drugs, devices, and therapies that are used to prevent or treat IRI in different organs, including the heart, liver, kidneys, and brain. These treatments may include medications to prevent inflammation and oxidative stress, mechanical devices to improve blood flow, or surgical procedures to restore blood flow to the affected area.
2018 to 2022 Ischemia Reperfusion Injury Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Ischemia reperfusion injury treatment reflected a value of 3.4% during the historical period, 2018 to 2022.
Factors driving the growth of the ischemia reperfusion injury treatment market during this period include an increase in the incidence of ischemia-related disorders such as heart attacks, strokes, and organ transplants, as well as the development of new and innovative therapies to address these conditions.
Additionally, the market has seen an increase in collaborations and partnerships between pharmaceutical and medical device companies, as well as increased investment in research and development to advance the development of new therapies and technologies.
Thus, the market for Ischemia reperfusion injury treatment is expected to register a CAGR of 6.1% in the forecast period 2023 to 2033.
Market Competition
Key players in the ischemia reperfusion injury treatment market are Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., Zealand Pharma A/S, Faraday Pharmaceuticals and SBI Pharmaceuticals
- Amyndas Pharmaceuticals has developed a drug candidate called AMY-101, which is a HSP inducer that has shown promising results in preclinical studies. The drug has been shown to reduce tissue damage and improve functional recovery in animal models of myocardial infarction, stroke, and kidney ischemia reperfusion injury.
- Bolder Biotechnology has developed a drug candidate called BBT-015, which is a modified form of human serum albumin (HSA). BBT-015 has been engineered to include a domain called H-NOX, which can bind to and modulate nitric oxide (NO) signaling in the body. Nitric oxide is a key signaling molecule involved in many physiological processes, including blood vessel dilation, immune cell function, and inflammation.
Key Companies Profiled
- Amyndas Pharmaceuticals LLC
- Angion
- Bolder Biotechnology
- Opsona Therapeutics Ltd.
- Pharming Group NV
- Prolong Pharmaceuticals
- Prothix BV
- Stealth BioTherapeutics, Inc.
- Zealand Pharma A/S
- Faraday Pharmaceuticals
- SBI Pharmaceuticals
Key Segments Profiled in the Ischemia Reperfusion Injury Treatment Industry Survey
Indication:
- Heart injury
- Kidney injury
- Intestine injury
- Other injury
End-user:
- Hospitals
- Specialty Clinics
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
